UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the month of July 2026

 

Commission File Number 001-15170

 

 

GSK plc

(Translation of registrant's name into English)

 

 

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	7 (partnership shares)
			£19.6290	7 (matching shares)
d)	Aggregated information
	Aggregated volume Price	14 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	3
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification /amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	34
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	11
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

  

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	70
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	28
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	45
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	58
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification /amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	54
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	57
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6297	216
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

 

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Iain Whyte
b)	Position/status	PCA of Victoria Whyte (SVP & Company Secretary)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)   ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6297	1,050
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales: 

No. 3888792

Registered Office:

79 New Oxford Street

London 

WC1A 1DG

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)
Date: July 13, 2026
	By:/s/ VICTORIA WHYTE --------------------------
	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc